Disease · MONDO_0006920

prediabetes syndrome

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. prediabetes syndrome. Diseases, record MONDO_0006920. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006920

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: prediabetes syndrome; Open Targets
Open Targets ID: MONDO_0006920; Open Targets
Other names: Prediabetic State, borderline diabetes, prediabetes; Open Targets
Disease Ontology: DOID:11716; Disease Ontology
MeSH: D011236; MeSH
NCI Thesaurus: C122685; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 13 of its 48 drugs, from ClinicalTrials.gov; Open Targets

Drugs48

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
METFORMIN	CHEMBL1431	Small molecule	Phase 3	ClinicalTrials.gov	20	20	20	Drugs and targets
SEMAGLUTIDE	CHEMBL2108724	Protein	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
LIRAGLUTIDE	CHEMBL4084119	Protein	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
DAPAGLIFLOZIN	CHEMBL429910	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
INSULIN GLARGINE	CHEMBL1201497	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
LINAGLIPTIN	CHEMBL237500	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ROFLUMILAST	CHEMBL193240	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ARGININE	CHEMBL1485	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
COLESEVELAM	CHEMBL6068331		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
COLESEVELAM HYDROCHLORIDE	CHEMBL1201473		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 48

See all 48 drugs

Targets105

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SLC5A2	Sodium/glucose cotransporter 2	4	Sodium/glucose cotransporter 2 inhibitor	Phase 3	https://conductscience.org/library/genes/6524	Drugs and targets
COXFA4	Mitochondrial complex I (NADH dehydrogenase)	2	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 3	https://conductscience.org/library/genes/4697	Drugs and targets
COXFA4L2	Mitochondrial complex I (NADH dehydrogenase)	2	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 3	https://conductscience.org/library/genes/56901	Drugs and targets
DPP4	Dipeptidyl peptidase 4	2	Dipeptidyl peptidase IV inhibitor	Phase 3	https://conductscience.org/library/genes/1803	Drugs and targets
GLP1R	Glucagon-like peptide 1 receptor	2	Glucagon-like peptide 1 receptor agonist	Phase 3	https://conductscience.org/library/genes/2740	Drugs and targets
GPD2	Glycerol-3-phosphate dehydrogenase, mitochondrial	2	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor	Phase 3	https://conductscience.org/library/genes/2820	Drugs and targets
INSR	Insulin receptor	2	Insulin receptor agonist	Phase 3	https://conductscience.org/library/genes/3643	Drugs and targets
MT-ND1	Mitochondrial complex I (NADH dehydrogenase)	2	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 3	https://conductscience.org/library/genes/4535	Drugs and targets
MT-ND2	Mitochondrial complex I (NADH dehydrogenase)	2	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 3	https://conductscience.org/library/genes/4536	Drugs and targets
MT-ND3	Mitochondrial complex I (NADH dehydrogenase)	2	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 3	https://conductscience.org/library/genes/4537	Drugs and targets

1 to 10 of 105

See all 105 targets

Trials66

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01926041	The Effectiveness of Smoking Cessation in Prediabetic Smokers	Not applicable	589	2023-02-22	Diabetes Mellitus, Cigarette Smoking, Prediabetes	VARENICLINE	Its record names the disease	ClinicalTrials.gov
NCT00570739	Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.	Phase 3	502	2010-07-13	Type 2 Diabetes Mellitus, Hypercholesterolemia, Pre-diabetes	COLESEVELAM HYDROCHLORIDE, METFORMIN	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT01779362	RISE Adult Medication Study	Phase 3	267	2023-05-11	Prediabetes, Type 2 Diabetes	INSULIN GLARGINE, LIRAGLUTIDE, METFORMIN	Its record names the disease	ClinicalTrials.gov
NCT05040971	Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes	Phase 3	207	2024-10-28	Obesity	SEMAGLUTIDE	Its record names the disease	ClinicalTrials.gov
NCT02470403	Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index	Phase 2	181	2017-05-12	Elevated Body Mass Index	LICOGLIFLOZIN	Its record names the disease	ClinicalTrials.gov
NCT03968224	Effectiveness of Dapagliflozin for Weight Loss	Phase 2/3	160	2025-10-15	PreDiabetes, Obesity, Morbid, Diabetes Mellitus, Type 2	DAPAGLIFLOZIN, METFORMIN	Its record names the disease	ClinicalTrials.gov
NCT01779375	RISE Pediatric Medication Study	Phase 3	91	2018-10-09	Prediabetes, Type 2 Diabetes	INSULIN GLARGINE, METFORMIN	Its record names the disease	ClinicalTrials.gov
NCT01763346	Beta Cell Restoration Through Fat Mitigation	Not applicable	88	2019-10-21	Prediabetes, Type 2 Diabetes, Obesity	METFORMIN	Its record names the disease	ClinicalTrials.gov
NCT02330549	ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD	Phase 2	45	2019-10-11	Prediabetic State, Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus	CENICRIVIROC	Its record names the disease	ClinicalTrials.gov
NCT01488409	Effects of Acipimox on Mitochondrial Function in Obesity	Phase 2	39	2016-02-03	Abdominal Obesity, Insulin Resistance, Hypertriglyceridemia	ACIPIMOX	Its record names the disease	ClinicalTrials.gov

1 to 10 of 66

See all 66 trials

Comparisons in its trials30

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Intervention (FIT2 Program) vs Usual Care: Number of Participants With New-onset Type 2 Diabetes Mellitus (DM)	83 of 279	134 of 310	589	NCT01926041	Trial comparisons
Intervention (FIT2 Program) vs Usual Care: Number of Participants With Regression to Normoglycemia	43 of 279	25 of 310	589	NCT01926041	Trial comparisons
Intervention (FIT2 Program) vs Usual Care: deaths from any cause	0 of 279	0 of 310	589	NCT01926041	Trial comparisons
Intervention (FIT2 Program) vs Usual Care: serious adverse events	0 of 279	0 of 310	589	NCT01926041	Trial comparisons
Semaglutide 2.4 mg vs Placebo: deaths from any cause	2 of 138	0 of 69	207	NCT05040971	Trial comparisons
Semaglutide 2.4 mg vs Placebo: serious adverse events	12 of 138	6 of 69	207	NCT05040971	Trial comparisons
Metformin/Dapagliflozin vs Metformin: deaths from any cause	0 of 54	0 of 55	109	NCT03968224	Trial comparisons
Metformin/Dapagliflozin vs Metformin: serious adverse events	0 of 54	0 of 55	109	NCT03968224	Trial comparisons
Metformin Alone vs Glargine Followed by Metformin: deaths from any cause	0 of 47	0 of 44	91	NCT01779375	Trial comparisons
Metformin Alone vs Glargine Followed by Metformin: serious adverse events	5 of 47	2 of 44	91	NCT01779375	Trial comparisons

1 to 10 of 30

See all 30 comparisons in its trials

Papers from its trials52

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39089293	RESULT	1	PubMed
30282699	RESULT	1	PubMed
29941500	RESULT	1	PubMed
29941497	RESULT	2	PubMed
29860335	RESULT	1	PubMed
20167359	RESULT	1	PubMed
18191683	RESULT	1	PubMed
17909087	RESULT	1	PubMed
17317382	RESULT	1	PubMed
15031036	RESULT	1	PubMed

1 to 10 of 52

See all 52 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006920

GET https://conductscience.org/api/diseases/v1/MONDO_0006920/drugs?page=2

API reference For AI assistants